Background: Drug-drug interplay (DDI) is a critical public well being challenge. The L1000 database of the LINCS undertaking has collected hundreds of thousands of genome-wide expressions induced by 20,000 small molecular compounds on 72 cell traces. Whether or not this unified and complete transcriptome information useful resource can be utilized to construct a greater DDI prediction mannequin continues to be unclear. Due to this fact, we developed and validated a novel deep studying mannequin for predicting DDI utilizing 89,970 recognized DDIs extracted from the DrugBank database (model 5.1.4).
Outcomes: The proposed mannequin consists of a graph convolutional autoencoder community (GCAN) for embedding drug-induced transcriptome information from the L1000 database of the LINCS undertaking; and an extended short-term reminiscence (LSTM) for DDI prediction. Comparative analysis of varied machine studying strategies demonstrated the superior efficiency of our proposed mannequin for DDI prediction. Lots of our predicted DDIs have been revealed within the newest DrugBank database (model 5.1.7). Within the case research, we predicted medication interacting with sulfonylureas to trigger hypoglycemia and medicines interacting with metformin to trigger lactic acidosis, and confirmed each to induce results on the proteins concerned within the metabolic mechanism in vivo.
Conclusions: The proposed deep studying mannequin can speed up the invention of recent DDIs. It could actually help future medical analysis for safer and simpler drug co-prescription.
Human Type 2 Diabetes Leukopak |
|||
ABC-TC4311 | AcceGen | 1 pack | Ask for price |
Description: Non-RI dependent diabetes, or Type 2 Diabetes, is characterized by hyperglycemia that is caused by a combination of RI resistance and the body's s inability to compensate by producing more RI. |
Diabetes (Type 1) Exosome RNA |
|||
P241-DB1 | 101Bio | - | Ask for price |
Diabetes (Type 2) Exosome RNA |
|||
P241-DB2 | 101Bio | - | Ask for price |
Human Type I Diabetes Peripheral Blood Mononuclear Cells |
|||
ABC-TC4263 | AcceGen | 1 vial | Ask for price |
Description: Peripheral blood mononuclear cells are isolated from Type I Diabetes peripheral blood by diluting the whole blood with PBS and using gradient separation techniques. After centrifugation,the mononuclear cell layer is collected. Mononuclear Cells can be processed further to isolate subpopulations. Fresh Diabetic Type I PBMCs is available upon request. |
Human Type II Diabetes PB Plasma |
|||
ABC-TC4266 | AcceGen | 1 vial | Ask for price |
Description: Type II Diabetes peripheral blood plasma is obtained by centrifugation of the Type II Diabetes PB. This product has a diminished number of cells and platelets. Fresh Diabetic Type II PB plasma is available upon request. |
Human iPS Cell Line (Type 2 Diabetes) |
|||
CSC-00849L | Creative Bioarray | One Frozen vial | Ask for price |
Single Donor Human Type II Diabetes Urine |
|||
IRHUURESDIBTII250ML | Innovative research | each | EUR 1063 |
Description: Single Donor Human Type II Diabetes Urine |
Single Donor Human Type II Diabetes Urine |
|||
IRHUURESDIBTII50ML | Innovative research | each | EUR 439 |
Description: Single Donor Human Type II Diabetes Urine |
Human Muscle Myoblasts, Diabetes Type II |
|||
ABC-TC3957 | AcceGen | 1 vial | Ask for price |
Description: Diabetic Type I and Type II HSMM-Human Skeletal Muscle Myoblasts are isolated from donors diagnosed with either Diabetes Type I or Diabetes Type II. Additional donor information is available by contacting Scientific Support. |
HighQC™ Human IPS Cell (Type 2 Diabetes) |
|||
ABC-SC0005T | AcceGen | 1 vial | Ask for price |
Description: Induced Pluriopotent Stem Cells (iPSCs) are a type of pluripotent stem cells that can be derived directly from adult somatic cells . The derived iPSCs can propagate indefinitely, as well as give rise to other cell types in the body. iPS cells, thus, hold great promise in the field of regenerative medicine by representing a single source of cells that could be used to replace those damaged/diseased cells. |
Human Type II Diabetes Peripheral Blood Mononuclear Cells |
|||
ABC-TC4265 | AcceGen | 1 vial | Ask for price |
Description: Human Peripheral Blood Mononuclear Cells are available as positive and negative controls for T-cell monitoring in ELISPOT, ELISA, cytokine bead array, tetramer/pentamer, and flow cytometry assays. A peripheral blood mononuclear cell is defined as any blood cell with a round nucleus. These blood cells are a critical component in the immune system to fight infection and adapt to intruders. The lymphocyte population consists of CD4+ and CD8+ T cells, B cells and Natural Killer cells, CD14+ Monocytes, and Basophils/Neutrophils/Eosinophils/Dendritic cells. These cells are often extracted from whole blood or from leukopacks using ficoll, a hydrophilic polysaccharide that separates layers of blood, with monocytes and lymphocytes forming a buffy coat under a layer of plasma.Samples from each donor are tested via PCR to confirm non-reactivity. Peripheral blood mononuclear cells are isolated from Type II Diabetes peripheral blood by diluting the whole blood with PBS and using gradient separation techniques. After centrifugation,the mononuclear cell layer is collected. Mononuclear Cells can be processed further to isolate subpopulations. Fresh Diabetic Type II PBMCs is available upon request. |
HighQC™ Human IPS Cell (Episomal/ Diabetes Type II/ Adipose) |
|||
ABC-SC0011T | AcceGen | 1 vial | Ask for price |
Description: Gentaur offers human iPS cell lines derived from PBMCs, dermal fibroblasts, or adipose tissue of patients with Parkinson's Disease (PD) and Diabetes II. These iPS cells are established from a single clone and expanded in feeder-free conditions. |
HighQC™ Human IPS Cell (IPSC From PBMC/ Diabetes Type II/ Episomal) |
|||
ABC-SC0009T | AcceGen | 1 vial | Ask for price |
Description: Gentaur offers human iPS cell lines derived from PBMCs, dermal fibroblasts, or adipose tissue of patients with Parkinson's Disease (PD) and Diabetes II. These iPS cells are established from a single clone and expanded in feeder-free conditions. |
HighQC™ Human IPS Cell (IPSC From Fibroblast/ Diabetes Type II/ Episomal) |
|||
ABC-SC0010T | AcceGen | 1 vial | Ask for price |
Description: Gentaur is is proud to offer human iPS cell lines derived from the human dermal fibroblasts from patients with Type 2 Diabetes (T2D). The pertinent donor information is available upon request. These iPS cells are established from a single clone and expanded in feeder-free conditions. Normal human iPS cell lines are also available as separate products . We also provide custom iPSC generation and iPSC differentiation services to meet your needs. |
Linearity FD Special Diabetes |
|||
K889M-5 | Audit MicroControls | 5 x 2 mL | EUR 374 |
HighQC™ Human Bone Marrow Derived Mesenchymal Stem Cell/ Type II Diabetes Patient |
|||
ABC-SC0027T | AcceGen | 1 vial | Ask for price |
Description: Human MSCs (Bone Marrow Derived) from a single adult donor clinically diagnosed with Type II Diabetes. The MSCs are compatible with our MSC Expansion Medium for Bone Marrow Derived MSCs.All of the cells provided are tested and are negative for HIV-1, HIV-2, Hepatitis B and Hepatitis C as detected by PCR. The cells are confirmed to be negative for mycoplasma and other detectable microbial contamination. |
Single Donor Human Diabetes Serum |
|||
ISERSDIB | Innovative research | each | EUR 209 |
Description: Single Donor Human Diabetes Serum |
Human Diabetes Lung Tissue Lysate |
|||
IHULGDIBTL100UG | Innovative research | each | EUR 1413 |
Description: Human Diabetes Lung Tissue Lysate |
Single Donor Human Diabetes Plasma |
|||
IPLASDIB | Innovative research | each | EUR 209 |
Description: Single Donor Human Diabetes Plasma |
Human Diabetes Ileum Tissue Lysate |
|||
IHUILMDIBTL100UG | Innovative research | each | EUR 1413 |
Description: Human Diabetes Ileum Tissue Lysate |
Human Diabetes Colon Tissue Lysate |
|||
IHUCLNDIBTL100UG | Innovative research | each | EUR 1413 |
Description: Human Diabetes Colon Tissue Lysate |
Human Diabetes Jejunum Tissue Lysate |
|||
IHUJEJDIBTL100UG | Innovative research | each | EUR 1413 |
Description: Human Diabetes Jejunum Tissue Lysate |
Human Diabetes Stomach Tissue Lysate |
|||
IHUSTDIBTL100UG | Innovative research | each | EUR 1413 |
Description: Human Diabetes Stomach Tissue Lysate |
Human Diabetes Duodenum Tissue Lysate |
|||
IHUDUODIBTL100UG | Innovative research | each | EUR 1413 |
Description: Human Diabetes Duodenum Tissue Lysate |
Human Diabetes Pancreas Tissue Lysate |
|||
IHUPCSDIBTL100UG | Innovative research | each | EUR 1413 |
Description: Human Diabetes Pancreas Tissue Lysate |
Human Diabetes Esophagus Tissue Lysate |
|||
IHUESOPDIBTL100UG | Innovative research | each | EUR 1413 |
Description: Human Diabetes Esophagus Tissue Lysate |
Human Diabetes AdiposeVisceral Tissue Lysate |
|||
IHUADPTVDIBTL100UG | Innovative research | each | EUR 2663 |
Description: Human Diabetes AdiposeVisceral Tissue Lysate |
Human Diabetes Skeletal Muscle Tissue Lysate |
|||
IHUSKMDIBTL100UG | Innovative research | each | EUR 1413 |
Description: Human Diabetes Skeletal Muscle Tissue Lysate |
Diabetes Drug Leads Bioactive Peptide Library |
|||
L-012 | PHOENIX PEPTIDE | 160 peptides | EUR 7938 |
Human Diabetes AdiposeSubcutaneous Tissue Lysate |
|||
IHUADPTSDIBTL100UG | Innovative research | each | EUR 2663 |
Description: Human Diabetes AdiposeSubcutaneous Tissue Lysate |
Human Diabetes Pancreas Lysate Membrane Fraction |
|||
IHUPCSDIBTLM100UG | Innovative research | each | EUR 1199 |
Description: Human Diabetes Pancreas Lysate Membrane Fraction |
Linearity FLQ Special Diabetes for Roche Systems |
|||
K929M-5 | Audit MicroControls | 5 x 2 mL | EUR 374 |
Linearity FLQ Special Diabetes for Abbott Systems |
|||
K956M-5 | Audit MicroControls | 5 x 2 mL | EUR 374 |
Human Diabetes Skeletal Muscle Lysate Membrane Fraction |
|||
IHUSKMDIBTLM100UG | Innovative research | each | EUR 1199 |
Description: Human Diabetes Skeletal Muscle Lysate Membrane Fraction |
HighQC™ Induced Pluripotent Stem Cell, From Diabetes (mellitus) |
|||
ABC-SC0241 | AcceGen | 1 vial | Ask for price |
Description: Diabetes (mellitus), Primary cell type: Fibroblast, Unknown vector detectable; Cells are only guaranteed with purchase of Gentaur Media and Gentaur Extra Cellular Matrix for appropriate cell culture, for 30 days from the date of shipment. |
Rrad (GFP-tagged) - Mouse Ras-related associated with diabetes (Rrad) |
|||
MG204351 | Origene Technologies GmbH | 10 µg | Ask for price |
Rrad (untagged) - Mouse Ras-related associated with diabetes (Rrad), (10ug) |
|||
MC203288 | Origene Technologies GmbH | 10 µg | Ask for price |
Rrad (untagged ORF) - Rat Ras-related associated with diabetes (Rrad), (10 ug) |
|||
RN208148 | Origene Technologies GmbH | 10 µg | Ask for price |
Rrad (Myc-DDK-tagged) - Mouse Ras-related associated with diabetes (Rrad) |
|||
MR204351 | Origene Technologies GmbH | 10 µg | Ask for price |
Rrad (Myc-DDK-tagged ORF) - Rat Ras-related associated with diabetes (Rrad), (10 ug) |
|||
RR208148 | Origene Technologies GmbH | 10 µg | Ask for price |
RRAD (untagged)-Human Ras-related associated with diabetes (RRAD), transcript variant 1 |
|||
SC322965 | Origene Technologies GmbH | 10 µg | Ask for price |
RRAD (untagged)-Human Ras-related associated with diabetes (RRAD), transcript variant 2 |
|||
SC117559 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF clone of Rrad (mGFP-tagged) - Mouse Ras-related associated with diabetes (Rrad) |
|||
MR204351L4 | Origene Technologies GmbH | 10 µg | Ask for price |
RRAD (GFP-tagged) - Human Ras-related associated with diabetes (RRAD), transcript variant 2 |
|||
RG202927 | Origene Technologies GmbH | 10 µg | Ask for price |
RRAD (GFP-tagged) - Human Ras-related associated with diabetes (RRAD), transcript variant 1 |
|||
RG225433 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF clone of Rrad (Myc-DDK-tagged) - Mouse Ras-related associated with diabetes (Rrad) |
|||
MR204351L3 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF clone of Rrad (mGFP-tagged ORF) - Rat Ras-related associated with diabetes (Rrad), (10 ug) |
|||
RR208148L4 | Origene Technologies GmbH | 10 µg | Ask for price |
RRAD (Myc-DDK-tagged)-Human Ras-related associated with diabetes (RRAD), transcript variant 2 |
|||
RC202927 | Origene Technologies GmbH | 10 µg | Ask for price |
RRAD (Myc-DDK-tagged)-Human Ras-related associated with diabetes (RRAD), transcript variant 1 |
|||
RC225433 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF clone of Rrad (Myc-DDK-tagged ORF) - Rat Ras-related associated with diabetes (Rrad), (10 ug) |
|||
RR208148L3 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF clone of Human Ras-related associated with diabetes (RRAD), transcript variant 2, mGFP tagged |
|||
RC202927L4 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF clone of Human Ras-related associated with diabetes (RRAD), transcript variant 1, mGFP tagged |
|||
RC225433L2 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF clone of Human Ras-related associated with diabetes (RRAD), transcript variant 1, mGFP tagged |
|||
RC225433L4 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF particles, Rrad (GFP-tagged) - Mouse Ras-related associated with diabetes (Rrad), 200ul, >10^7 TU/mL |
|||
MR204351L4V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF particles, Rrad (GFP-tagged ORF) - Rat Ras-related associated with diabetes (Rrad), 200ul, >10^7 TU/mL |
|||
RR208148L4V | Origene Technologies GmbH | 200 µl | Ask for price |
3`UTR clone of Ras-related associated with diabetes (RRAD) transcript variant 2 for miRNA target validation |
|||
SC205326 | Origene Technologies GmbH | 10 µg | Ask for price |
3`UTR clone of Ras-related associated with diabetes (RRAD) transcript variant 1 for miRNA target validation |
|||
SC205328 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF clone of Human Ras-related associated with diabetes (RRAD), transcript variant 2, Myc-DDK-tagged |
|||
RC202927L3 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF clone of Human Ras-related associated with diabetes (RRAD), transcript variant 1, Myc-DDK-tagged |
|||
RC225433L1 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF clone of Human Ras-related associated with diabetes (RRAD), transcript variant 1, Myc-DDK-tagged |
|||
RC225433L3 | Origene Technologies GmbH | 10 µg | Ask for price |
Lenti ORF particles, Rrad (Myc-DDK-tagged) - Mouse Ras-related associated with diabetes (Rrad), 200ul, >10^7 TU/mL |
|||
MR204351L3V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF particles, Rrad (Myc-DDK-tagged ORF) - Rat Ras-related associated with diabetes (Rrad), 200ul, >10^7 TU/mL |
|||
RR208148L3V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF particles, RRAD (mGFP-tagged) - Human Ras-related associated with diabetes (RRAD), transcript variant 2, 200ul, >10^7 TU/mL |
|||
RC202927L4V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF particles, RRAD (mGFP-tagged) - Human Ras-related associated with diabetes (RRAD), transcript variant 1, 200ul, >10^7 TU/mL |
|||
RC225433L2V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF particles, RRAD (mGFP-tagged) - Human Ras-related associated with diabetes (RRAD), transcript variant 1, 200ul, >10^7 TU/mL |
|||
RC225433L4V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF particles, RRAD (Myc-DDK tagged) - Human Ras-related associated with diabetes (RRAD), transcript variant 2, 200ul, >10^7 TU/mL |
|||
RC202927L3V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF particles, RRAD (Myc-DDK tagged) - Human Ras-related associated with diabetes (RRAD), transcript variant 1, 200ul, >10^7 TU/mL |
|||
RC225433L1V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF particles, RRAD (Myc-DDK tagged) - Human Ras-related associated with diabetes (RRAD), transcript variant 1, 200ul, >10^7 TU/mL |
|||
RC225433L3V | Origene Technologies GmbH | 200 µl | Ask for price |
GCK (untagged)-Human glucokinase (hexokinase 4, maturity onset diabetes of the young 2), transcript variant 1 (cDNA clone MGC:1742 IMAGE:3536582) |
|||
SC127236 | Origene Technologies GmbH | 10 µg | Ask for price |
HighQC™ Diabetic Type I And Type II Adipose Derived Stem Cell |
|||
ABC-SC2109 | AcceGen | 1 vial | Ask for price |
Description: Human Adipose Derived Stem Cells (ADSC) from normal (non-diabetic) donors are available as a separate product. These cells have demonstrated very similar phenotypic and functional characteristics to that of bone marrow-derived mesenchymal stem cells. Diabetic Human Adipose Derived Stem Cells (ADSC) have been reported to differentiate down many different lineages including chondrogenic, osteogenic, adipogenic and neural. Diabetic Human Adipose Derived Stem Cells (ADSC) have been cryopreserved at primary passage. |
Human Dermal Microvascular EndoCells Diabetic Type I |
|||
ABC-TC3401 | AcceGen | 1 vial | Ask for price |
Description: Diseased endothelial cells are isolated from human donors that have been diagnosed with diabetes type I or type II disease. Diseased cells are grown in the same optimized media system as normal human dermal microvascular endothelial cells. |
Human Cardiac Microvascular Endothelial Cells Diabetic Type I |
|||
ABC-TC3269 | AcceGen | 1 vial | Ask for price |
Description: Diseased endothelial cells are isolated from human donors that have been diagnosed with diabetes type I or type II disease. Diseased cells are grown in the same optimized media system as normal human cardiac microvascular endothelial cells. Diabetic HMVE |
Pooled Human Semen |
|||
IRHUSM100ML | Innovative research | each | EUR 3800 |
Description: Pooled Human Semen |
Pooled Human Semen |
|||
IRHUSM1ML | Innovative research | each | EUR 88 |
Description: Pooled Human Semen |
Pooled Human Semen |
|||
IRHUSM20ML | Innovative research | each | EUR 905 |
Description: Pooled Human Semen |
Pooled Human Semen |
|||
IRHUSM5ML | Innovative research | each | EUR 341 |
Description: Pooled Human Semen |
Semen Identifier Kit |
|||
ML200-5R | EWC Diagnostics | 1 unit | EUR 6.63 |
Description: Semen Identifier Kit |
Single Donor Human Semen |
|||
IRHUSMS100ML | Innovative research | each | EUR 4120 |
Description: Single Donor Human Semen |
Single Donor Human Semen |
|||
IRHUSMS1ML | Innovative research | each | EUR 100 |
Description: Single Donor Human Semen |
Single Donor Human Semen |
|||
IRHUSMS20ML | Innovative research | each | EUR 962 |
Description: Single Donor Human Semen |
Single Donor Human Semen |
|||
IRHUSMS5ML | Innovative research | each | EUR 360 |
Description: Single Donor Human Semen |
Pooled Human Semen Cryopreserved |
|||
IRHUSMCRYP0.5ML | Innovative research | each | EUR 1170 |
Description: Pooled Human Semen Cryopreserved |
Hemacytometer-Disposable(Semen Test) |
|||
DHC-S022 | INCYTO | 20pcs/box | EUR 68.9 |
Hemacytometer-Disposable(Semen Test) |
|||
DHC-S025 | INCYTO | 50pcs/box | EUR 132.5 |
Single Donor Human Semen Swab |
|||
IRHUSSMSWB5 | Innovative research | each | EUR 3188 |
Description: Single Donor Human Semen Swab |
Prostate Specific Antign (Human Semen) |
|||
P1444-50 | Biovision | each | EUR 261.6 |
Single Donor Vasectomized Human Semen |
|||
IRHUSSMVSC1 | Innovative research | each | EUR 457 |
Description: Single Donor Vasectomized Human Semen |
Single Donor Vasectomized Human Semen |
|||
IRHUSSMVSC5 | Innovative research | each | EUR 2175 |
Description: Single Donor Vasectomized Human Semen |
Prostatic Acid Phosphatase, Human Semen |
|||
P1445-1 | Biovision | each | EUR 627.6 |
PSA-ACT Complex, Human Semen & Serum |
|||
P1448-10 | Biovision | each | EUR 405.6 |
Innovative Grade US Origin Bovine Semen |
|||
IGBOSMF | Innovative research | each | EUR 203 |
Description: Innovative Grade US Origin Bovine Semen |
Innovative Grade US Origin Bovine Semen |
|||
IGBOSMZ | Innovative research | each | EUR 203 |
Description: Innovative Grade US Origin Bovine Semen |
Human Dermal Microvascular EndoCells Diabetic Type II |
|||
ABC-TC3402 | AcceGen | 1 vial | Ask for price |
Description: Diseased endothelial cells are isolated from human donors that have been diagnosed with diabetes type I or type II disease. Diseased cells are grown in the same optimized media system as normal human dermal microvascular endothelial cells. |
Genorise® Semen DNA Extraction Kit 1000 |
|||
GR101016 | Genorise Scientific | 1000 | EUR 1045 |
Genorise® Semen DNA Extraction Kit 500 |
|||
GR101041 | Genorise Scientific | 500 | EUR 480 |
Genorise® Semen DNA Extraction Kit 200 |
|||
GR101042 | Genorise Scientific | 200 | EUR 258 |
Genorise® Semen DNA Extraction Kit 100 |
|||
GR101043 | Genorise Scientific | 100 | EUR 144 |
Genorise® Semen DNA Extraction Kit 50 |
|||
GR101044 | Genorise Scientific | 50 | EUR 87 |
Human Cardiac Microvascular Endothelial Cells Diabetic Type II |
|||
ABC-TC3270 | AcceGen | 1 vial | Ask for price |
Description: Diseased endothelial cells are isolated from human donors that have been diagnosed with diabetes type I or type II disease. Diseased cells are grown in the same optimized media system as normal human cardiac microvascular endothelial cells. Diabetic HMVE |
Genorise® Semen Stain DNA Extraction Kit 1000 |
|||
GR101017 | Genorise Scientific | 1000 | EUR 1045 |
Genorise® Semen Stain DNA Extraction Kit 500 |
|||
GR101069 | Genorise Scientific | 500 | EUR 564 |
Genorise® Semen Stain DNA Extraction Kit 200 |
|||
GR101070 | Genorise Scientific | 200 | EUR 243 |
Genorise® Semen Stain DNA Extraction Kit 100 |
|||
GR101071 | Genorise Scientific | 100 | EUR 144 |
Genorise® Semen Stain DNA Extraction Kit 50 |
|||
GR101072 | Genorise Scientific | 50 | EUR 87 |
AI-91K LN2 Freezer for Bulk Semen Storage, no controller |
|||
TW-AI-91K | MiTeGen | 1 UNIT | EUR 66671 |
Description: AI-91K LN2 Freezer for Bulk Semen Storage, no controller |
Semenogelin I Protein |
|||
20-abx261182 | Abbexa |
|
|
Semenogelin I Protein |
|||
abx261182-10g | Abbexa | 10 µg | EUR 325 |
Semenogelin I Protein |
|||
abx261182-2g | Abbexa | 2 µg | EUR 225 |
Semenogelin I antibody |
|||
70R-1587 | Fitzgerald | 100 ug | EUR 407 |
Description: Rabbit polyclonal Semenogelin I antibody raised against the N terminal of SEMG1 |
Semenogelin I antibody |
|||
70R-1593 | Fitzgerald | 100 ug | EUR 407 |
Description: Rabbit polyclonal Semenogelin I antibody raised against the C terminal of SEMG1 |
Semenogelin I antibody |
|||
70R-5491 | Fitzgerald | 50 ug | EUR 467 |
Description: Rabbit polyclonal Semenogelin I antibody raised against the middle region of SEMG1 |
Semenogelin I (SEMG1) Antibody |
|||
20-abx322135 | Abbexa |
|
|
Semenogelin I (SEMG1) Antibody |
|||
20-abx320262 | Abbexa |
|
|
Semenogelin I (SEMG1) Antibody |
|||
20-abx129235 | Abbexa |
|
|
Semenogelin I (SEMG1) Antibody |
|||
20-abx174508 | Abbexa |
|
|
Semenogelin I (SEMG1) Antibody |
|||
abx237711-100ug | Abbexa | 100 ug | EUR 661.2 |
Semenogelin I (SEMG1) Antibody |
|||
20-abx115422 | Abbexa |
|
|
Semenogelin I (SEMG1) Antibody |
|||
20-abx004204 | Abbexa |
|
|
Semenogelin I (SEMG1) Antibody |
|||
abx028130-400ul | Abbexa | 400 ul | EUR 627.6 |
Semenogelin I (SEMG1) Antibody |
|||
abx028130-80l | Abbexa | 80 µl | EUR 343.2 |
Semenogelin I (SEMG1) Antibody |
|||
abx004204-100l | Abbexa | 100 µl | EUR 400 |
Semenogelin I (SEMG1) Antibody |
|||
abx004204-20l | Abbexa | 20 µl | EUR 175 |
Semenogelin I (SEMG1) Antibody |
|||
abx004204-50l | Abbexa | 50 µl | EUR 275 |
Semenogelin I (SEMG1) Antibody |
|||
abx115422-100l | Abbexa | 100 µl | EUR 612.5 |
Semenogelin I (SEMG1) Antibody |
|||
abx129235-100l | Abbexa | 100 µl | EUR 275 |
Semenogelin I (SEMG1) Antibody |
|||
abx129235-1ml | Abbexa | 1 ml | EUR 750 |
Semenogelin I (SEMG1) Antibody |
|||
abx129235-200l | Abbexa | 200 µl | EUR 337.5 |
Semenogelin I (SEMG1) Antibody |
|||
abx237711-100g | Abbexa | 100 µg | EUR 350 |
Semenogelin I (SEMG1) Antibody |
|||
abx028130-400l | Abbexa | 400 µl | EUR 518.75 |
Semenogelin I (SEMG1) Antibody |
|||
abx174508-100l | Abbexa | 100 µl | EUR 787.5 |
Semenogelin I (SEMG1) Antibody |
|||
abx174508-1ml | Abbexa | 1 ml | Ask for price |
Semenogelin I (SEMG1) Antibody |
|||
abx174508-200l | Abbexa | 200 µl | Ask for price |
Semenogelin I (SEMG1) Antibody |
|||
abx320262-100l | Abbexa | 100 µl | EUR 350 |
Semenogelin I (SEMG1) Antibody |
|||
abx320262-50l | Abbexa | 50 µl | EUR 237.5 |
Semenogelin I (SEMG1) Antibody |
|||
abx322135-100g | Abbexa | 100 µg | EUR 350 |
Semenogelin I (SEMG1) Antibody |
|||
abx322135-50g | Abbexa | 50 µg | EUR 237.5 |
Recombinant Semenogelin I (SEMG1) |
|||
RPU51622-100ug | Biomatik Corporation | 100ug | EUR 492.8 |
Recombinant Semenogelin I (SEMG1) |
|||
RPU51622-1mg | Biomatik Corporation | 1mg | EUR 2184 |
Recombinant Semenogelin I (SEMG1) |
|||
RPU51622-50ug | Biomatik Corporation | 50ug | EUR 396 |
Recombinant Semenogelin I (SEMG1) |
|||
RPH185Hu01 | Cloud-Clone | 10ug | EUR 160 |
Recombinant Semenogelin I (SEMG1) |
|||
4-RPH185Hu01 | Cloud-Clone |
|
|
Description: Recombinant Human Semenogelin I expressed in: E.coli |
Semenogelin I Blocking Peptide |
|||
33R-3239 | Fitzgerald | 100 ug | EUR 119 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of SEMG1 antibody, catalog no. 70R-1593 |
Semenogelin I Blocking Peptide |
|||
33R-4289 | Fitzgerald | 100 ug | EUR 119 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of SEMG1 antibody, catalog no. 70R-5491 |
Semenogelin I Blocking Peptide |
|||
33R-7601 | Fitzgerald | 100 ug | EUR 119 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of SEMG1 antibody, catalog no. 70R-1587 |
Semenogelin I Human Recombinant |
|||
rAP-4051 | Angio Proteomie | Inquiry | Ask for price |
Human Semenogelin I ELISA Kit |
|||
IHUSEMG1KT | Innovative research | each | EUR 733 |
Description: Human Semenogelin I ELISA Kit |
Diabeton |
|||
413648 | MedKoo Biosciences | 5.0g | EUR 234 |
Human Semenogelin I (SEMG1) Protein |
|||
20-abx168081 | Abbexa |
|
|
Human Semenogelin I (SEMG1) Protein |
|||
abx168081-1ml | Abbexa | 1 ml | EUR 212.5 |
ELISA Kit for Semenogelin I (SEMG1) |
|||
SEH185Hu | Cloud-Clone | 96Т | EUR 700 |
Human Semenogelin I (SEMG1) CLIA Kit |
|||
20-abx495402 | Abbexa |
|
|
Human Semenogelin I (SEMG1) ELISA Kit |
|||
DLR-SEMG1-Hu | DL Develop | 96T | EUR 463 |
Description: serum, plasma, seminal plasma or other biological fluids. |
Human Semenogelin I (SEMG1) ELISA Kit |
|||
DLR-SEMG1-Hu-48T | DL Develop | 48T | EUR 620.4 |
Description: A sandwich quantitative ELISA assay kit for detection of Human Semenogelin I (SEMG1) in samples from serum, plasma, seminal plasma or other biological fluids. |
Human Semenogelin I (SEMG1) ELISA Kit |
|||
DLR-SEMG1-Hu-96T | DL Develop | 96T | EUR 807.6 |
Description: A sandwich quantitative ELISA assay kit for detection of Human Semenogelin I (SEMG1) in samples from serum, plasma, seminal plasma or other biological fluids. |
Human SEMG1(Semenogelin I) ELISA Kit |
|||
ELK4641-48T | ELK Biotech | 48T | Ask for price |
Description: The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Human SEMG1. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Human SEMG1. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Human SEMG1, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Human SEMG1 in the samples is then determined by comparing the OD of the samples to the standard curve. |
Human SEMG1(Semenogelin I) ELISA Kit |
|||
ELK4641-96T | ELK Biotech | 96T | Ask for price |
Description: The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Human SEMG1. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Human SEMG1. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Human SEMG1, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Human SEMG1 in the samples is then determined by comparing the OD of the samples to the standard curve. |
Human Semenogelin I (SEMG1) ELISA Kit |
|||
EKU07271-48T | Biomatik Corporation | 48T | EUR 555.66 |
Human Semenogelin I (SEMG1) ELISA Kit |
|||
EKU07271-5x96T | Biomatik Corporation | 5x96T | EUR 3770.55 |
Human Semenogelin I (SEMG1) ELISA Kit |
|||
EKU07271-96T | Biomatik Corporation | 96T | EUR 793.8 |
Human Semenogelin I (SEMG1) ELISA Kit |
|||
EKN48382-48T | Biomatik Corporation | 48T | EUR 378.7 |
Human Semenogelin I (SEMG1) ELISA Kit |
|||
EKN48382-5x96T | Biomatik Corporation | 5x96T | EUR 2569.75 |
Human Semenogelin I (SEMG1) ELISA Kit |
|||
EKN48382-96T | Biomatik Corporation | 96T | EUR 541 |
Human Semenogelin I (SEMG1) ELISA Kit |
|||
DL-SEMG1-Hu | DL Develop | 96T | EUR 441 |
Description: serum, plasma, seminal plasma or other biological fluids. |
Human Semenogelin I (SEMG1) ELISA Kit |
|||
EK16572 | SAB | 96Т | EUR 768 |
Human Semenogelin I (SEMG1) ELISA Kit |
|||
abx571776-96tests | Abbexa | 96 tests | EUR 904.8 |
Human Semenogelin I (SEMG1) ELISA Kit |
|||
abx250766-96tests | Abbexa | 96 tests | EUR 904.8 |
Human Semenogelin I (SEMG1) ELISA Kit |
|||
20-abx153055 | Abbexa |
|
|
Human Semenogelin I (SEMG1) ELISA Kit |
|||
RD-SEMG1-Hu-48T | Reddot Biotech | 48T | EUR 452.7 |
Description: serum, plasma, seminal plasma and other biological fluids. |
Human Semenogelin I (SEMG1) ELISA Kit |
|||
RD-SEMG1-Hu-48Tests | Reddot Biotech | 48 Tests | EUR 625.2 |
Human Semenogelin I (SEMG1) ELISA Kit |
|||
RD-SEMG1-Hu-96T | Reddot Biotech | 96T | EUR 646.7 |
Description: serum, plasma, seminal plasma and other biological fluids. |
Human Semenogelin I (SEMG1) ELISA Kit |
|||
RD-SEMG1-Hu-96Tests | Reddot Biotech | 96 Tests | EUR 867.6 |
Human Semenogelin I(SEMG1)ELISA Kit |
|||
QY-E01566 | Qayee Biotechnology | 96T | EUR 448.8 |
Human Semenogelin I (SEMG1) ELISA Kit |
|||
RDR-SEMG1-Hu-48T | Reddot Biotech | 48T | EUR 475.34 |
Description: serum, plasma, seminal plasma and other biological fluids. |
Human Semenogelin I (SEMG1) ELISA Kit |
|||
RDR-SEMG1-Hu-48Tests | Reddot Biotech | 48 Tests | EUR 652.8 |
Human Semenogelin I (SEMG1) ELISA Kit |
|||
RDR-SEMG1-Hu-96T | Reddot Biotech | 96T | EUR 679.04 |
Description: serum, plasma, seminal plasma and other biological fluids. |
Human Semenogelin I (SEMG1) ELISA Kit |
|||
RDR-SEMG1-Hu-96Tests | Reddot Biotech | 96 Tests | EUR 907.2 |
Human Semenogelin I (SEMG1) ELISA Kit |
|||
SEH185Hu-10x96wellstestplate | Cloud-Clone | 10x96-wells test plate | EUR 5677.8 |
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Semenogelin I (SEMG1) in serum, plasma, seminal plasma and other biological fluids. |
Human Semenogelin I (SEMG1) ELISA Kit |
|||
SEH185Hu-1x48wellstestplate | Cloud-Clone | 1x48-wells test plate | EUR 572.76 |
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Semenogelin I (SEMG1) in serum, plasma, seminal plasma and other biological fluids. |
Human Semenogelin I (SEMG1) ELISA Kit |
|||
SEH185Hu-1x96wellstestplate | Cloud-Clone | 1x96-wells test plate | EUR 766.8 |
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Semenogelin I (SEMG1) in serum, plasma, seminal plasma and other biological fluids. |
Human Semenogelin I (SEMG1) ELISA Kit |
|||
SEH185Hu-5x96wellstestplate | Cloud-Clone | 5x96-wells test plate | EUR 3090.6 |
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Semenogelin I (SEMG1) in serum, plasma, seminal plasma and other biological fluids. |
Human Semenogelin I (SEMG1) ELISA Kit |
|||
4-SEH185Hu | Cloud-Clone |
|
|
Description: Enzyme-linked immunosorbent assay based on the Double-antibody Sandwich method for detection of Human Semenogelin I (SEMG1) in samples from serum, plasma, seminal plasma and other biological fluids with no significant corss-reactivity with analogues from other species. |
Human Semenogelin I (SEMG1) ELISA Kit |
|||
SL2440Hu | Sunlong | 96 Tests | EUR 468 |
Semenogelin I (SEMG1) Polyclonal Antibody |
|||
CAU22029-100ul | Biomatik Corporation | 100ul | EUR 235.2 |
Semenogelin I (SEMG1) Polyclonal Antibody |
|||
CAU22029-200ul | Biomatik Corporation | 200ul | EUR 294 |
SEMG1 (untagged)-Human semenogelin I (SEMG1) |
|||
SC303261 | Origene Technologies GmbH | 10 µg | Ask for price |
ELISA kit for Human SEMG1 (Semenogelin I) |
|||
ELK4641 | ELK Biotech | 1 plate of 96 wells | EUR 518.4 |
Description: A sandwich ELISA kit for detection of Semenogelin I from Human in samples from blood, serum, plasma, cell culture fluid and other biological fluids. |
Polyclonal Antibody to Semenogelin I (SEMG1) |
|||
PAH185Hu01 | Cloud-Clone | 100ul | EUR 245 |
SEMG1 (GFP-tagged) - Human semenogelin I (SEMG1) |
|||
RG216046 | Origene Technologies GmbH | 10 µg | Ask for price |
Background: Diabetes and consuming problems are steadily comorbid. This explicit comorbidity just isn’t solely usually poorly recognised, however is tough to deal with and has a excessive mortality.
Methodology: On this article, we’ll briefly evaluation the connection between diabetes and consuming problems. We are going to evaluation the present NICE and different steering and studies regarding each diabetes and consuming problems in the UK. We are going to then describe the suggestions of the 2018 Welsh Authorities Consuming Dysfunction Service Evaluate and the 2021 the Scottish Authorities Consuming Dysfunction Service Evaluate concerning diabetes and consuming problems, which is able to result in service change.
Conclusions: We conclude that this can be a comparatively underdeveloped however necessary space the place there must be additional service improvement and extra collaboration between diabetes and consuming dysfunction providers.
Introduction: Sodium-glucose co-transporter-2 (SGLT2) inhibitors reasonably scale back glucose ranges in type-2 diabetes mellitus (T2DM). Some instances of diabetic ketoacidosis (DKA) have been reported with SGLT2 inhibitors. Nevertheless, information on the long-term security of dapagliflozin in Saudi Arabia are missing. The current research aimed to watch the protection of dapagliflozin in sufferers with T2DM and consider the change in HbA1c through the remark interval in comparison with baseline.
Strategies: This was an area, potential, single-arm, non-interventional, regulatory post-marketing research. The research was performed in Saudi Arabia from Might 2017 to September 2019. Sufferers acquired both 5 or 10 mg dapagliflozin together with weight loss program and train modifications to deal with T2DM. The incidence of antagonistic occasions was noticed over the therapy period and for Three days after administering the final dose of dapagliflozin.
Outcomes: A complete of 527 sufferers have been recruited within the research, 524 of which have been eligible for the statistical evaluation. About 62% have been males. The median (IQR) age was 52.3 (14.8) years, whereas the median (IQR) physique mass index was 31.6 (7.7) kg/m2. The median (IQR) period because the sufferers have been first identified with T2DM was 8.78 (6.73) years. The commonest comorbidities have been hyperlipidemia (51.1%) and hypertension (41.1%). Virtually three-quarters of the research inhabitants (73.7%) acquired different antidiabetic drugs along with dapagliflozin.
Over a interval of 12 months, a complete of 106 antagonistic occasions have been skilled by 65 (12.33%) sufferers. Vulvovaginal pruritus (3.1%), dysuria (2.7%), polyuria (1.3%), urinary tract infections (1%), fatigue (0.8%), and hypoglycemia (0.8%) have been among the many reported antagonistic occasions. One case of DKA (0.2%) was reported. The imply (SD) HbA1c% degree considerably decreased from 8.6 (1.6) % at baseline to succeed in 7.2 (1.2) % after 12 months of therapy (p < 0.0001).
Conclusion: Dapagliflozin was discovered to be a effectively tolerated and efficient therapy possibility for T2DM sufferers in Saudi Arabia. Vulvovaginal pruritus and dysuria have been the commonest antagonistic occasions.
Goals: To judge the long-term penalties of espresso ingesting in sufferers with kind 2 diabetes.
Information synthesis: PubMed, Scopus, and Net of Sciences have been searched to November 2020 for potential cohort research evaluating the affiliation of espresso ingesting with danger of heart problems (CVD) and mortality in sufferers with kind 2 diabetes. Two reviewers extracted information and rated the certainty of proof utilizing GRADE method. Random-effects fashions have been used to estimate the hazard ratios (HRs) and 95% CIs. Dose-response associations have been modeled by a one-stage mixed-effects meta-analysis. Ten potential cohort research with 82,270 instances have been included. In comparison with these with no espresso consumption,
the HRs for consumption of Four cups/d have been 0.79 (95%CI: 0.72, 0.87; n = 10 research) for all-cause mortality, 0.60 (95%CI: 0.46, 0.79; n = 4) for CVD mortality, 0.68 (95%CI: 0.51, 0.91; n = 3) for coronary coronary heart illness (CHD) mortality, 0.72 (95%CI: 0.54, 0.98; n = 2) for CHD, and 0.77 (95%CI: 0.61, 0.98; n = 2) for whole CVD occasions. There was no vital affiliation for most cancers mortality and stroke. There was an inverse monotonic affiliation between espresso ingesting and all-cause and CVD mortality, and inverse linear affiliation for CHD and whole CVD occasions. The understanding of proof was graded average for all-cause mortality, and low or very low for different outcomes.
Conclusions: Consuming espresso could also be inversely related to the danger of mortality in sufferers with kind 2 diabetes. Nevertheless, extra analysis is required contemplating kind of espresso, sugar and cream added to espresso, and historical past of CVD to current extra assured outcomes.